News | Proton Therapy | November 03, 2022

The MEVION S250-FIT would be the first and only proton therapy system that can be installed in an existing LINAC vault.

The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)

The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)


November 3, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS). Stanford Health Care has been selected as the first site where the system will be developed and installed.

Proton therapy is a precise form of radiation therapy that reduces the amount of unnecessary radiation exposure to healthy tissue, which has the potential to decrease or eliminate the treatment side effects and lessen the risk of secondary malignancies.

Historically, the size, cost, and inherent complexity of proton technologies have limited the adoption of proton therapy. Mevion believes that the MEVION S250-FIT system has the potential to overcome the practical challenges of other technologies because the system is designed to be a more compact, affordable solution that can fit into an existing LINAC vault. Today, new proton therapy centers in the U.S. are almost exclusively compact single-room systems. Mevion’s compact system would continue to advance the design and accessibility of proton therapy. The MEVION S250-FIT system is currently in development and has not received regulatory clearance for clinical use.

“Mevion is dedicated to making proton therapy deployment similar to conventional radiation by simplifying room renovation requirements, enabling faster installation, and facilitating integration with other radiation therapy modalities,” said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. “Through our arrangement with Stanford Health Care, Mevion is aiming to demonstrate that proton therapy can fit in an existing vault of a radiation oncology department and in turn become more accessible.”

For more information: www.mevion.com

*The MEVION S250-FIT Proton Therapy System has not received regulatory clearance.

 

Find more ASTRO22 content here


Related Content

News | Artificial Intelligence

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and ...

Time November 28, 2023
arrow
News | Treatment Planning

November 26, 2023 — TeleDaaS, PLLC, a leading dosimetry-as-a-service provider, made its official debut today at the ...

Time November 26, 2023
arrow
News | Breast Imaging

November 21, 2023 —iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and CancerIQ ...

Time November 21, 2023
arrow
News | Breast Imaging

November 20, 2023 — The American Society for Radiation Oncology (ASTRO) issued a clinical guideline on partial breast ...

Time November 20, 2023
arrow
News | Artificial Intelligence

November 15, 2023 — The 2023 Radiological Society of North America (RSNA) Alexander R. Margulis Award for Scientific ...

Time November 15, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As another month comes to a close, ITN takes a look at the Top 10 most-read pieces of content from www.itnonline.com ...

Time November 06, 2023
arrow
News | ASTRO

November 3, 2023 —The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time November 03, 2023
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Imaging advancements, including 3D Doppler imaging to detect cancers in numerous organs, are used to accurately guide ...

Time November 03, 2023
arrow
Feature | Radiation Oncology | By Christine Book

Howard Sandler, MD, FASTRO, Radiation Oncology Department Chair at Cedars-Sinai Medical Center, took the helm as ...

Time November 03, 2023
arrow
News | Artificial Intelligence

November 2, 2023 — GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with ...

Time November 02, 2023
arrow
Subscribe Now